Published in PLoS One on November 21, 2012
Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol (2013) 1.75
Advances in clinical management of eosinophilic esophagitis. Gastroenterology (2014) 1.48
Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol (2014) 1.22
Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut (2015) 1.13
Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology (2015) 1.11
Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study. Am J Gastroenterol (2015) 1.00
Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One (2014) 0.89
Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am (2015) 0.87
Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol Clin North Am (2014) 0.87
Systematic review: Eosinophilic esophagitis in Asian countries. World J Gastroenterol (2015) 0.86
White Paper AGA: Eosinophilic Esophagitis. Clin Gastroenterol Hepatol (2017) 0.85
Genetic and epigenetic underpinnings of eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 0.84
Eosinophilic esophagitis: historical perspective on an evolving disease. Gastroenterol Clin North Am (2014) 0.84
Diagnostics of eosinophilic esophagitis: clinical, endoscopic, and histologic pitfalls. Dig Dis (2014) 0.83
Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. Nat Rev Gastroenterol Hepatol (2015) 0.83
Clinicopathologic Analysis of Proton Pump Inhibitor-Responsive Esophageal Eosinophilia in Korean Patients. Gut Liver (2016) 0.82
Oesophageal baseline impedance values are decreased in patients with eosinophilic oesophagitis. United European Gastroenterol J (2013) 0.82
IgE Antibody Detection and Component Analysis in Patients with Eosinophilic Esophagitis. J Allergy Clin Immunol Pract (2015) 0.82
Management of refractory eosinophilic esophagitis. Dig Dis (2014) 0.82
Mechanisms of Disease of Eosinophilic Esophagitis. Annu Rev Pathol (2016) 0.81
Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice. Gastroenterol Hepatol (N Y) (2014) 0.80
Proton pump inhibitors for eosinophilic oesophagitis. Curr Opin Gastroenterol (2013) 0.78
Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase. J Allergy Clin Immunol (2016) 0.77
The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep (2016) 0.77
Lack of seasonal variation in the incidence of eosinophilic oesophagitis in adolescent and adult non-PPI-responsive oesophageal eosinophilia midwestern US populations. United European Gastroenterol J (2014) 0.77
An overview of eosinophilic esophagitis. Gut Liver (2014) 0.77
Eosinophilic oesophagitis: clinical presentation and pathogenesis. Postgrad Med J (2014) 0.77
Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences. Curr Opin Gastroenterol (2015) 0.76
Eosinophilic esophagitis in adults: An update. World J Gastrointest Pharmacol Ther (2016) 0.76
Proton pump inhibitor responsive esophageal eosinophilia, a distinct disease entity? World J Gastroenterol (2014) 0.76
Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Curr Treat Options Gastroenterol (2015) 0.76
Eosinophilic esophagitis: From pathophysiology to treatment. World J Gastrointest Pathophysiol (2015) 0.75
STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation. Immune Netw (2016) 0.75
Unmet therapeutic needs in eosinophilic esophagitis. Dig Dis (2014) 0.75
Managing eosinophilic esophagitis: challenges and solutions. Clin Exp Gastroenterol (2016) 0.75
Recent advances in understanding/managing eosinophilic esophagitis in adults. F1000Res (2015) 0.75
Recent discoveries and emerging therapeutics in eosinophilic esophagitis. World J Gastrointest Pharmacol Ther (2016) 0.75
MUC18 regulates IL-13-mediated airway inflammatory response. Inflamm Res (2017) 0.75
Management of refractory eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol (2017) 0.75
Prevalence of allergic rhinitis and asthma in patients with chronic rhinosinusitis and gastroesophageal reflux disease. Ann Allergy Asthma Immunol (2016) 0.75
Acid suppression therapy and allergic reactions. Allergo J Int (2015) 0.75
Recent advances in eosinophilic esophagitis. F1000Res (2017) 0.75
High-resolution profiling of histone methylations in the human genome. Cell (2007) 85.74
The complex language of chromatin regulation during transcription. Nature (2007) 16.97
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc (2006) 6.24
Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med (2000) 5.27
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol (2010) 3.43
RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. Nat Struct Mol Biol (2007) 3.36
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos (2004) 3.04
Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol (2006) 2.92
Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev (2006) 2.40
Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol (2007) 2.36
Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev (2006) 2.31
American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.23
Transcriptional regulation of mammalian genes in vivo. A tale of two templates. J Biol Chem (1997) 2.11
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut (2012) 2.00
Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res (2007) 1.92
Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci (2009) 1.91
The micro-environment of inflammation or Metchnikoff revisited. Lancet (1955) 1.54
Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS One (2008) 1.38
Eotaxin-3/CCL26 gene expression in intestinal epithelial cells is up-regulated by interleukin-4 and interleukin-13 via the signal transducer and activator of transcription 6. Int J Biochem Cell Biol (2005) 1.34
Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6. J Immunol (2001) 1.33
Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep (2008) 1.25
Acidosis of synovial fluid correlates with synovial fluid leukocytosis. Am J Med (1978) 1.12
Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol (2005) 1.07
Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol (2009) 1.06
Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology (1992) 1.03
Platelet-activating factor stimulates cytoplasmic alkalinization and granule acidification in human eosinophils. J Cell Sci (2004) 0.96
Differential roles of C-terminal activation motifs in the establishment of Stat6 transcriptional specificity. J Biol Chem (2003) 0.92
The role of vacuolar H(+)-ATPase in the control of intragranular pH and exocytosis in eosinophils. Lab Invest (1996) 0.86
Human esophageal epithelial cells possess an Na+/H+ exchanger for H+ extrusion. Am J Gastroenterol (1998) 0.82
Treatment of cells with n-alpha-tosyl-L-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor. Mol Immunol (2008) 0.79
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Duration of the interval between the completion of bowel preparation and the start of colonoscopy predicts bowel-preparation quality. Gastrointest Endosc (2009) 2.44
Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol (2007) 2.36
Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol (2003) 2.21
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis (2005) 2.09
Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology (2009) 2.05
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut (2012) 2.00
Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol (2007) 1.92
Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci (2009) 1.91
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology (2009) 1.72
Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol (2005) 1.72
Barrett's esophagus. N Engl J Med (2014) 1.67
Prone positioning of obese patients for colonoscopy results in shortened cecal intubation times: a randomized trial. Dig Dis Sci (2012) 1.62
The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. Dig Dis Sci (2011) 1.52
Is genomic evaluation feasible in endoscopic studies of Barrett's esophagus? A pilot study. Gastrointest Endosc (2006) 1.49
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci (2008) 1.38
Esophagitis dissecans superficialis ("sloughing esophagitis"): a clinicopathologic study of 12 cases. Am J Surg Pathol (2009) 1.37
Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin (2005) 1.22
Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut (2009) 1.20
Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol (2012) 1.20
Trains, tracks, and promotion in an academic medical center. Gastroenterology (2011) 1.18
Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology (2010) 1.18
Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.17
In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res (2009) 1.16
Hallmarks of cancer progression in Barrett's oesophagus. Lancet (2002) 1.13
The prophylactic placement of hemoclips to prevent delayed post-polypectomy bleeding: an unnecessary practice? A case control study. Dig Dis Sci (2014) 1.12
Low rate of postpolypectomy bleeding among patients who continue thienopyridine therapy during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.12
Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays. Int J Biol Sci (2008) 1.11
Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol (2012) 1.10
Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol (2005) 1.08
The attitudes of oncology physicians and nurses toward phase I, II, and III cancer clinical trials. Contemp Clin Trials (2011) 1.07
Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. Cancer Res (2009) 1.07
Current strategies in the management of intra-abdominal abscesses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 1.06
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J Biol Chem (2007) 1.06
Surgical bypass versus endoscopic stenting for malignant gastroduodenal obstruction: a decision analysis. Dig Dis Sci (2006) 1.04
Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2004) 1.04
Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus. Am J Gastroenterol (2005) 1.03
Third-generation human mitochondria-focused cDNA microarray and its bioinformatic tools for analysis of gene expression. Biotechniques (2007) 1.03
Information assimilation and distribution challenges and goals for real and virtual journals. J Clin Gastroenterol (2005) 1.02
TNFalpha activates c-Jun amino terminal kinase through p47(phox). Exp Cell Res (2002) 1.01
For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci (2009) 0.99
Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol (2010) 0.98
Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther (2009) 0.98
Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One (2012) 0.97
Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett (2008) 0.96
In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative effects through activation of the Chk2 pathway. Cancer Res (2007) 0.95
Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One (2010) 0.95
Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. J Clin Invest (2014) 0.92
Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses. Cancer Res (2012) 0.92
Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.92
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013) 0.92